Skip to main content
Premium Trial:

Request an Annual Quote

Just Swap It Out

Newer approaches may boost the number of conditions that gene therapies can treat, the Associated Press reports. It adds that there are currently about half a dozen approved gene therapies in the US and that there are some 400 gene therapy trials underway.

The main challenge facing gene therapy has been delivering the needed version of the gene to patients' cells, the AP adds, noting that therapies for blindness deliver the treatment right to the eye, while other therapies isolate patients' blood cells, alter them in the lab, and then return them to patients with a fixed gene.

Now, the AP says, other viral vectors, including HIV and AAV, are being explored as delivery vehicles. With this type of approach, it says that companies could largely just swap out the genes targeted to treat different diseases. "The only thing that's changing is the payload, the gene," Chris Mason, Avrobio's chief scientific officer, tells the AP.

The AP notes, though, that challenges remain. "Every time we think we have overcome the safety issues, we continue to butt up against them," Peter Marks from the US Food and Drug Administration tells it. "I have confidence that we will work through them ... but we can't get too sure of ourselves."

The Scan

Study Examines Insights Gained by Adjunct Trio RNA Sequencing in Complex Pediatric Disease Cases

Researchers in AJHG explore the diagnostic utility of adding parent-child RNA-seq to genome sequencing in dozens of families with complex, undiagnosed genetic disease.

Clinical Genomic Lab Survey Looks at Workforce Needs

Investigators use a survey approach in Genetics in Medicine Open to assess technologist applications, retention, and workforce gaps at molecular genetics and clinical cytogenetics labs in the US.

Study Considers Gene Regulatory Features Available by Sequence-Based Modeling

Investigators in Genome Biology set sequence-based models against observational and perturbation assay data, finding distal enhancer models lag behind promoter predictions.

Genetic Testing Approach Explores Origins of Blastocyst Aneuploidy

Investigators in AJHG distinguish between aneuploidy events related to meiotic missegregation in haploid cells and those involving post-zygotic mitotic errors and mosaicism.